Cytokine Gene Polymorphism in Sympathetic Ophthalmia

Atan, Denize; Turner, Steve J.; Kilmartin, Dara J.; Forrester, John V.; Bidwell, Jeff L.; Dick, Andrew D.; Churchill, Amanda J.

doi:10.1167/iovs.05-0126

Cited by 46 publications

(23 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…B-lymphocytes were also found to predominate in some patients in a study by Shah et al [54]. Cytokine gene polymorphisms may be markers of the severity of disease, recurrence and the necessary level of immunosuppression to control the ocular inflammation [3]. Genetic factors may be implicated since association with MHC haplotypes have been identified including HLA-DR4/ DQw3, HLA-DR4/DRw53, HLA-A11, HLA-B40, HLA DRB1*04 and HLA-DQB1*04 [35].…”

Section: Etiologymentioning

confidence: 94%

Sympathetic ophthalmia

Castiblanco

Adelman

2008

Graefes Arch Clin Exp Ophthalmol

104

View full text Add to dashboard Cite

show abstract

Section: Etiologymentioning

confidence: 94%

Sympathetic ophthalmia

Castiblanco

Adelman

2008

Graefes Arch Clin Exp Ophthalmol

104

View full text Add to dashboard Cite

show abstract

“…96,97 This is concordant with other smaller candidate single nucleotide polymorphism (SNP) analysis studies that show in sympathetic ophthalmia an association with IL-10-1082 SNP and three haplotype-tagging SNPs(htSNPs) in the IL10 gene, rs6703630, rs2222202, and rs3024490, are significantly associated with susceptibility to non-infectious uveitis, whereas a LTA þ 252AA/ TNFhtSNP2GG haplotype (rs909253 and rs361525) is protective. 98,99 Whether this will predict the outcome on an individual basis is unknown, 100 but it highlights how further GWAS and, more importantly, genomics, RNA sequencing, and transcriptomics, will shape our future approach by identifying new genes, potential biomarkers, and new targets for therapy. Examples are seen in cancer, where recently gene expression-based biomarkers have facilitated targeted chemotherapy but this is only recently being translated into autoimmunity, and in systemic vasculitis, a CD8 T cell transcriptomic profile has now been shown to predict prognosis in two distinct patient subgroups.…”

Section: How Do We Harness Our Approaches?mentioning

confidence: 99%

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Lee

Dick

2011

Eye

View full text Add to dashboard Cite

The blockbuster drug paradigm is under increasing scrutiny across the biopharmaceutical industry. Intraocular inflammation poses particular challenges to this, given the heterogeneity of conditions in the uveitis spectrum, and the increasing acknowledgement of individual patient and disease variance in underlying immune responses. This need has triggered a drive towards personalised and stratified medicine, supported and enabled as a result of continued development of both experimental models and molecular biological techniques and improved clinical classification. As such we have the ability now to systematically appraise at a genomic, transcriptomic, and proteomic level individual immunophenotype, and the promise that in the eye this can be augmented by in vivo immune imaging to identify individual immunopathology. With such advances all running in parallel, we are entering an era of experimental medicine that will facilitate early diagnosis, generate biomarkers for accurate prognostication, and enable the development of individualised and targeted therapies, which can progress rapidly into clinical practice.

show abstract

“…4 Gupta et al 5 report successful management of refractory sympathetic ophthalmia with infliximab. Because high-dose systemic steroid and immunosuppression therapy did not control inflammation in our patient, we used adalimumab, an anti-TNF factor monoclonal antibody.…”

Section: Discussionmentioning

confidence: 99%

Bilateral uveitis after phakic intraocular lens implantation and management with adalimumab

Soheilian

Jabbarpourbonyadi

Soheilian

et al. 2012

Journal of Cataract and Refractive Surgery

View full text Add to dashboard Cite

A 25-year-old woman with myopia who had an AC pIOL implantation in the left eye and posterior chamber pIOL implantation in the right eye developed bilateral granulomatous panuveitis 2 months after the second surgery. Physical examination showed bilateral Koeppe and Busacca nodules. Fluorescein angiography showed diffuse vascular and retinal pigment epithelial leakage in both eyes. With assessment of sympathetic ophthalmia, treatment with a high-dose systemic steroid was started. Oral cyclosporine and azathioprine were later added. Because the uveitis was not controlled, adalimumab was added. After 6 doses of adalimumab (40 mg subcutaneously), the uveitis subsided and corticosteroid and other immunosuppressive agents were tapered. Refractive AC pIOL implantation should be added to the list of intraocular procedures that may induce sympathetic ophthalmia. Adalimumab may have a therapeutic role in its management.

show abstract

Cytokine Gene Polymorphism in Sympathetic Ophthalmia

Abstract: These results show that cytokine gene polymorphisms are markers for the severity of disease in SO. They were found to be associated with recurrence of previously stable disease and with the level of maintenance steroid treatment required to control inflammatory activity.

Cited by 46 publications

References 42 publications

Sympathetic ophthalmia

Sympathetic ophthalmia

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Bilateral uveitis after phakic intraocular lens implantation and management with adalimumab

Contact Info

Product

Resources

About